Resolvin D6 (RvD6) is a specialized pro-resolving mediator (SPM) belonging to the D-series resolvin family, enzymatically synthesized from docosahexaenoic acid (DHA) during the active resolution phase of inflammation. Unlike anti-inflammatory drugs that merely suppress inflammatory signaling, RvD6 actively orchestrates the return to tissue homeostasis by inhibiting neutrophil recruitment, enhancing macrophage-mediated clearance of apoptotic cells (Efferocytosis), reducing pro-inflammatory cytokine production, and promoting wound healing.
Imagine a city recovering from a riot. The initial police response (acute inflammation) has stopped the violence, but now the streets are littered with debris, broken glass, and overturned cars (cellular damage and apoptotic cells). The city needs more than just "stop rioting" orders—it needs an active cleanup crew.
RvD6 is like the city manager who arrives with three specialized teams: (1) traffic controllers who redirect new police units away from the scene (stop neutrophil recruitment), (2) sanitation crews with specialized equipment to clear wreckage and safely remove damaged vehicles (macrophages doing efferocytosis), and (3) construction workers who repair the infrastructure (wound healing signals). The manager doesn't just tell everyone to "calm down"—she actively coordinates the transition from emergency response to reconstruction. If the city is deficient in cleanup crews (low SPM production due to poor omega-3 status), the debris piles up, attracting scavengers and creating a breeding ground for further chaos—this is chronic inflammation.
RvD6 biosynthesis occurs through stereoselective enzymatic conversion of DHA during Lipid mediator class switching:
Biosynthetic Pathway:
DHA (22:6ω-3) → 15-LOX oxygenation → 17-hydroperoxy-DHA → subsequent reduction and isomerization → RvD6 (17R,21-dihydroxy-docosa-4Z,7Z,10Z,12E,14E,19Z-hexaenoic acid)
Receptor Signaling:
RvD6 binds to G-protein coupled receptors (GPCRs) on target cells, though the specific high-affinity receptor for RvD6 is still under investigation. Related D-series resolvins signal through:
Cellular Actions:
-
Neutrophil Regulation:
- Blocks CXCL1 and IL-8 chemokine gradients
- Reduces L-selectin (CD62L) expression → decreased endothelial adhesion
- Inhibits transendothelial migration
- Promotes neutrophil apoptosis at inflammation site
-
Macrophage Reprogramming:
- Shifts macrophages from M1 macrophages (pro-inflammatory) to M2 macrophages (pro-resolving) phenotype
- Upregulates efferocytic receptors (CD36, C1q)
- Enhances phosphatidylserine recognition on apoptotic cells
- Stimulates TGF-beta and IL-10 secretion (anti-inflammatory)
- Reduces TNF-α, IL-1β, IL-6 production
-
Resolution Programming:
- Activates downstream signaling: GPCR → increased cAMP → PKA activation → CREB phosphorylation
- Triggers Autophagy pathways for cellular debris clearance
- Upregulates annexin A1 (amplifies resolution)
- Reduces NF-kB nuclear translocation
graph TD
A["DHA 22:6ω-3"] -->|15-LOX| B[17-HpDHA]
B -->|Reduction| C[RvD6]
C -->|GPCR binding| D["↑ cAMP"]
D -->|PKA activation| E[CREB phosphorylation]
C --> F[Neutrophil effects]
F --> F1["↓ CXCL1/IL-8 response"]
F --> F2["↓ CD62L expression"]
F --> F3["↑ Apoptosis at site"]
C --> G[Macrophage effects]
G --> G1["M1 → M2 shift"]
G --> G2["↑ Efferocytosis"]
G --> G3["↑ IL-10, TGF-β"]
G --> G4["↓ TNF-α, IL-1β, IL-6"]
C --> H[Tissue repair]
H --> H1["↑ Collagen deposition"]
H --> H2["↑ Angiogenesis factors"]
Metabolic Inactivation:
RvD6 is enzymatically inactivated through:
- Eicosanoid oxidoreductase conversion to 17-oxo-RvD6 (inactive)
- β-oxidation
- Half-life in vivo: approximately 30-60 minutes (requires continuous synthesis)
cPNI Diagnostic Framework:
RvD6 deficiency is a marker of resolution failure, a state where the body cannot exit the inflammatory phase despite resolution of the initial trigger. This aligns with Metamodel 5 (immune system dysregulation) and the concept of Metaflammation—chronic low-grade inflammation driven not by ongoing tissue damage but by failed resolution machinery.
Patient Populations:
-
Chronic Inflammatory Conditions:
-
Metabolic Dysfunction:
- Insulin resistance correlates inversely with SPM biosynthesis capacity
- Obesity—adipose tissue macrophages fail to switch from M1 to M2 phenotype
- Fatty Liver Disease—hepatic stellate cells show reduced resolvin receptor expression
-
Neurodegenerative Disease:
- Alzheimer's Disease—brain tissue shows 90% reduction in RvD1-6 compared to age-matched controls
- Microglial activation perpetuates without resolution phase
Intervention Strategy (Resoleomics):
The goal is to restore endogenous SPM production, not merely supplement:
-
Substrate Provision:
- Omega-3 supplementation: EPA+DHA 2-4g/day (target omega-3 index >8%)
- Measure: Red blood cell membrane DHA % (clinical threshold: <4% = deficiency)
-
Enzyme Optimization:
- Reduce Oxidative Stress (impairs 15-LOX function): vitamin E 400 IU, Selenium 200 μg
- Aspirin (75-100 mg) triggers COX-2 acetylation → aspirin-triggered resolvin synthesis (AT-RvD1)
- Address metabolic acidosis (pH <7.35 inhibits lipoxygenase activity)
-
Clearance Support:
- Enhance Efferocytosis: adequate vitamin D (25-OH >75 nmol/L), vitamin A, zinc
- Reduce saturated fat (blocks CD36 efferocytic receptor)
-
Clinical Biomarkers:
- Lipidomic profiling: SPM:leukotriene ratio (resolution index)
- CRP decline rate post-acute insult (measures resolution kinetics)
- Resolution indices: Tâ‚…â‚€ (time to 50% neutrophil reduction), Râ‚…â‚€ (time to 50% resolution)
Evolutionary Perspective:
Modern diets contain omega-6:omega-3 ratios of 15-20:1 (vs. ancestral 1-4:1), fundamentally shifting eicosanoid precursor pools away from resolvins toward Leukotriene B4 and Prostaglandin E2. This represents an Evolutionary mismatch—our resolution machinery evolved expecting regular omega-3 intake from marine/wild foods. The selfish immune system (Selfish immune system) will prioritize inflammatory responses when resolution mediators are scarce, defaulting to chronic inflammation as the metabolically "safer" option.
- RvD6 structure: 17R,21-dihydroxy-docosa-4Z,7Z,10Z,12E,14E,19Z-hexaenoic acid (MW ~360 Da)
- Produced at nanomolar concentrations (0.1-10 nM at inflamed sites) during resolution phase (24-72h post-injury)
- Synthesis requires functional 15-lipoxygenase and adequate cellular DHA (>4% of membrane phospholipids)
- Clinical deficiency threshold: Plasma RvD6 <50 pg/mL correlates with resolution failure in surgical recovery studies
- Half-life in circulation: 30-60 minutes (must be continuously synthesized)
- Works synergistically with RvD1, RvD5, Maresins, and Protectins (amplification effect)
- Oxidative Stress (lipid peroxidation) degrades RvD6 to inactive 17-oxo metabolites
- Aspirin (75-100 mg/day) enhances D-series resolvin production via COX-2 acetylation
- Target therapeutic range: Omega-3 index >8% to support adequate SPM biosynthesis
- Clinical pearl: SPM deficiency is NOT diagnosed by low omega-3 intake alone—requires assessment of conversion capacity (15-LOX genotype, oxidative status, metabolic health)
- Specialized pro-resolving mediators (SPMs) — RvD6 is a member of this superfamily of endogenous resolution mediators
- Resolvins — specific subfamily; RvD6 belongs to D-series (DHA-derived) branch
- RvD1 — structurally related D-series resolvin with similar but non-redundant functions
- RvD5 — another D-series resolvin; acts synergistically with RvD6
- DHA — essential omega-3 precursor; RvD6 cannot be synthesized without adequate DHA substrate
- 15-LOX — rate-limiting enzyme for RvD6 biosynthesis from DHA
- Lipid mediator class switching — cellular process enabling transition from pro-inflammatory eicosanoids to pro-resolving resolvins
- Efferocytosis — RvD6 enhances macrophage clearance of apoptotic neutrophils via CD36 and MerTK upregulation
- M2 macrophages — RvD6 drives macrophage polarization toward this pro-resolving phenotype
- R₅₀ — resolution endpoint (50% neutrophil reduction); RvD6 accelerates achievement of this target
- Resolution indices — quantitative measures of resolution kinetics that RvD6 directly influences
- Chronic inflammation — results from failed resolution when RvD6 and other SPMs are deficient
- Oxidative Stress — impairs 15-LOX function and degrades RvD6, creating vicious cycle
- Omega-3 — dietary intervention to restore DHA substrate availability for RvD6 synthesis
- Neutrophil — primary cellular target; RvD6 stops recruitment and promotes apoptosis
- IL-10 — anti-inflammatory cytokine upregulated by RvD6-activated macrophages
- TNF-α — pro-inflammatory cytokine suppressed by RvD6 signaling
- NF-kB — transcription factor whose nuclear translocation is blocked by RvD6
- Metaflammation — chronic low-grade inflammation state characterized by SPM deficiency
- Insulin resistance — metabolic consequence of failed resolution in adipose tissue
- COX-2 acetylation — aspirin-induced modification enabling production of aspirin-triggered resolvins
- GPR32 — putative receptor for D-series resolvins in humans
- Maresins — related SPM family derived from DHA; works synergistically with RvD6
- Protectins — another DHA-derived SPM family contributing to resolution
Module 5 - Day 1: